Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
CymaBay Therapeutics, Inc. (CBAY)
|
Add to portfolio |
|
|
|
| Price: |
$4.23
| | Metrics |
| OS: |
98.2
|
M
| |
|
|
| Market cap: |
$415
|
M
| |
|
|
|
Net cash:
|
$214
|
M
| |
$2.18
|
per share
|
|
EV:
|
$201
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.0 | 0.0 | 113.3 | 0.0 | 10.0 | 0.0 | 0.0 |
| Revenue growth | | | -100.0% | | -100.0% | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 113.3 | 0.0 | 10.0 | 0.0 | 0.0 |
| Gross margin | | | | 100.0% | | 100.0% | | |
| Research and development | 68.0 | 64.5 | 35.9 | 83.8 | 58.1 | 18.9 | 15.9 | 17.0 |
| General and administrative | 25.1 | 23.0 | 16.7 | 19.2 | 14.4 | 12.4 | 9.6 | 8.9 |
| EBIT | -93.1 | -87.6 | -52.6 | -98.0 | -72.5 | -21.3 | -25.6 | -25.9 |
| EBIT margin | | | | -86.5% | | -213.3% | | |
| Pre-tax income | -106.0 | -90.0 | -51.0 | -102.8 | -72.5 | -27.6 | -26.7 | -15.5 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -106.0 | -90.0 | -51.0 | -102.8 | -72.5 | -27.6 | -26.7 | -15.5 |
| Net margin | | | | -90.8% | | -275.6% | | |
| |
| Diluted EPS | ($1.21) | ($1.27) | ($0.74) | ($1.53) | ($1.25) | ($0.79) | ($1.14) | ($0.82) |
| Shares outstanding (diluted) | 87.8 | 71.1 | 68.9 | 67.0 | 57.8 | 34.9 | 23.4 | 18.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|